ロード中...
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
BACKGROUND: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the inc...
保存先:
| 出版年: | Ann Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5834072/ https://ncbi.nlm.nih.gov/pubmed/28057664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw695 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|